logo
Researchers make alarming discovery while studying world's largest wild goat: 'Serious concerns'

Researchers make alarming discovery while studying world's largest wild goat: 'Serious concerns'

Yahoo15-06-2025

A new study has uncovered a troubling reality in the Himalayas: the world's largest wild goat is losing its home.
As livestock grazing spreads deeper into the alpine zones of the Kashmir region, the already-threatened Kashmir markhor is running out of space and options, according to recent reporting. Scientists say the species may be getting pushed into lower, less nutritious habitats at a critical time in their life cycle.
As detailed by Mongabay, markhor usually migrate to higher elevations in May and June to give birth and graze on nutritious alpine plants. But this timing now overlaps with a major influx of livestock — mostly sheep and goats — brought in by local herders.
Researchers found that livestock outnumber markhor by more than 30 to 1 during this critical period, pushing them into lower, less suitable areas.
That shift may be hurting young markhors. In one heavily grazed valley, researchers found far fewer yearlings compared with adult females — a sign that fewer kids are surviving their first year.
"This research raises serious concerns for markhor conservation in the region," said Tawqir Bashir, an assistant professor at Sher-e-Kashmir University, per Mongabay. "The severe competition with livestock for space and resources in summer, combined with the disturbance by herders and herding dogs, will affect their migration patterns as well."
According to Mongabay, there are only two viable markhor populations in India, in the Pir Panjal and Kazinag ranges. The subspecies is legally protected and classified as "near threatened" by the International Union for Conservation of Nature.
Forced into less than optimal habitats — especially after giving birth — females may struggle to recover body weight and provide for their young, increasing their vulnerability heading into harsh winters.
Markhor aren't the only hooved wildlife impacted, either, according to Mongabay. This may indicate a collapse of biodiversity, which could create ripple effects that impact the livelihoods of locals by resulting in habitat degradation and lost tourism income.
While the study raises red flags, it also points toward solutions. The researchers recommend protecting fawning sites and regulating livestock access in key areas during summer months.
Do you think America has a plastic waste problem?
Definitely
Only in some areas
Not really
I'm not sure
Click your choice to see results and speak your mind.
"The study provides a sustainable and ecologically sound solution to address this issue by recommending regulation of livestock," Mongabay wrote when paraphrasing Bashir.
Programs like the Kashmir Markhor Recovery Project, launched in 2004, have helped stabilize populations before. Rotational grazing — adopted in parts of India and Kenya — shows how people and wildlife can share the land more sustainably.
Saving the markhor isn't just about one species. These mountain grazers help keep fragile ecosystems in balance — ecosystems that millions depend on for water, food, and clean air.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

Yahoo

time2 days ago

  • Yahoo

Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments. Key Fiscal 2025 Highlights First three patients treated in Hemopurifier® cancer trial at Australian sites Indian regulatory approval received to initiate a similar oncology study Study protocol expanded to reflect evolving immunotherapy standard of care Preclinical data demonstrate 98.5% removal of platelet-derived EVs in simulated Hemopurifier® treatment Collaboration with UCSF to investigate Long COVID with findings to be presented at the Keystone Symposium Operating expenses reduced significantly through streamlined operations Clinical Progress in Cancer Trial Aethlon completed Hemopurifier treatments in the first three participants enrolled in its safety, feasibility, and dose-finding study of patients with solid tumors unresponsive to anti-PD-1 agents. Participant #1 was treated at Royal Adelaide Hospital in January 2025, while Participants #2 and #3 received treatment at Royal North Shore Hospital in Sydney in June 2025. All participants completed a single 4-hour Hemopurifier treatment without device deficiencies or immediate complications and have now completed the pre-specified 7-day safety follow-up. This milestone triggers the first meeting of an independent Data Safety Monitoring Board (DSMB), to review safety data and recommend advancement to the second treatment cohort. In the next cohort, participants will receive two Hemopurifier treatments during a one-week period. Preliminary data from the first cohort, including effects on extracellular vesicle (EV) removal and anti-tumor T-cell activity, are expected in approximately three months. In parallel, the trial protocol was amended to broaden eligibility to include patients receiving combination therapies with Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®), in line with current treatment practices. Currently, only about 30% of patients receiving pembrolizumab or nivolumab experience lasting clinical responses. EVs released by tumors have been implicated in cancer progression and resistance to anti-PD-1 therapies. The Hemopurifier® is designed to bind and remove these EVs from the bloodstream, potentially improving the therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of EVs in cancer patient plasma samples. As a reminder, the primary endpoint for the approximate 9 to 18-patient study is safety. The trials will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals. Patients who do not respond to the PD-1 antibody therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2, or 3 Hemopurifier treatments during a one-week period. In addition to safety, the study includes exploratory analyses evaluating how many Hemopurifier® treatments are needed to decrease the concentration of EVs, and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These findings are intended to guide the design of future safety and efficacy trials, including a potential Premarket Approval (PMA) study required by the FDA and other global regulatory agencies. Regulatory Approval India On June 19, 2025, the Company received formal approval from India's Central Drugs Standard Control Organization (CDSCO) to initiate a similar trial at Medanta Medicity Hospital. The approval followed a meeting with the Subject Expert Committee and prior Ethics Committee clearance. The trial will begin following a Site Initiation Visit (SIV) conducted by Aethlon's India-based CRO, Qualtran. Preclinical Study Supports Broader Applications On May 12, 2025, the results from Aethlon's preclinical ex vivo study were published in bioRxiv, and the manuscript has been submitted to a peer-reviewed journal for publication. Those results showed that the Hemopurifier, using proprietary Galanthus nivalis agglutin (GNA) affinity resin, removed 98.5% of platelet -derived extracellular vesicles (PD-EVs) from human plasma during a timepoint equivalent to a 4-hour HP treatment. Excessive levels of PD-EVs have been implicated in a myriad of diseases, including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer's disease, sepsis, acute and Long COVID. The results of this study support the ongoing oncology trial in Australia and suggest potential applications of the Hemopurifier in other EV-associated diseases. The manuscript describing this study has been submitted to a peer-reviewed journal for publication. Scientific Collaboration in Long COVID Research Aethlon's collaborative research with the UCSF Long COVID Clinic was accepted for a poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes (August 10-13, 2025). The study analyzed blood samples from participants with Long COVID as well as controls that had recovered from COVID-19 infection to evaluate the binding of larger and smaller extracellular vesicles to the Hemopurifier's lectin affinity resin, respectively. These findings build on prior clinical evidence and support further investigation of the Hemopurifier in Long COVID, an unmet medical need affecting approximately 44 and 48 million people in the United States alone, with an estimated economic burden of 2 billion dollars in those with symptoms lasting a year. Operational Achievements In fiscal 2025, Aethlon streamlined operations and significantly reduced its operating expenses, positioning the company for sustained focus on its clinical and regulatory goals. Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025 As of March 31, 2025, Aethlon had a cash balance of approximately $5.5 million. Consolidated operating expenses for the fiscal year ended March 31, 2025, were approximately $9.3 million, representing a decrease of $3.3 million or approximately 26%, compared to $12.6 million for the fiscal year ended March 31, 2024. This reduction was primarily driven by lower payroll and related expenses, professional fees, and general and administrative costs. Payroll and related expenses declined by an approximate $1.3 million, reflecting an approximate $900,000 reduction in salaries and related expenses and an approximate $800,000 decrease in stock-based compensation. These reductions were primarily attributable to the termination of three executives—one in the fiscal year 2024, one in July and October 2024—and a workforce reduction of non-executive staff in August 2024. The decrease in stock-based compensation was primarily due to the absence of accelerated vesting charges recognized in the prior year related to the termination of our former Chief Executive Officer, as well as reduced expenses following the departure of executives and staff. These decreases were partially offset by an increase of approximately $400,000 in severance expenses associated with the termination of two former executives. Professional fees also declined by approximately $1.3 million. This decrease includes $600,000 in legal costs savings resulting from a transition to a new legal firm, and an approximate $500,000 related to the termination of services with a contract manufacturing organization and the completion of a project that involved using an outside lab to process samples. Consulting fees related to scientific projects and regulatory projects declined by approximately $300,000. These reductions were partially offset by an approximate $85,000 increase in accounting fees associated with obtaining audit firm consents for various securities filings. General and administrative expenses decreased by approximately $660,000. The reduction was driven primarily by a $534,000 reduction in costs related to fewer raw material purchases, no cleanroom certification expenses, and reduced reliance on outside services for maintenance of the manufacturing facility. Laboratory supplies and testing costs also declined by $337,000 following the completion of oncology and transplant-related projects. Insurance expenses decreased by $141,000, reflecting lower medical and workers' compensation premiums due to reduced headcount, as well as an overall decrease in business insurance costs. Additional reductions included $44,000 in travel and entertainment expenses, $24,000 decrease in office supplies, and $19,000 in depreciation expense related to the disposal of certain equipment. These decreases were partially offset by a $467,000 increase in clinical trial expenses associated with our ongoing oncology study in Australia. As a result of the above factors, our operating loss decreased to $9.3 million for the fiscal year ended March 31, 2025, from $12.6 million for the fiscal year ended March 31, 2024. Other Income (Expense) Other expenses for the year ended March 31, 2025, included a non-cash charge of approximately $4.6 million related to a warrant inducement offer. In March 2025, we offered certain warrant holders the opportunity to exercise existing warrants at a temporarily reduced exercise price in exchange for the issuance of new warrants. The inducement expense recognized represents the combined fair value of the new warrants issued and the incremental fair value resulting from the modification of the exercise price of the existing warrants. This transaction did not impact cash flows from operating activities. During the fiscal year ended March 31, 2025, we recognized approximately $324,450 in other income related to the Employee Retention Tax Credit (ERTC) under the CARES Act and subsequent legislation. We recorded the ERTC as other income in the periods in which the payments were received. In addition, we recognized $36,339 in interest income related to the ERTC during fiscal 2025. As of March 31, 2025, the remaining expected credit was recorded as a receivable within other current assets on our consolidated balance sheet. No amounts were recorded in the prior fiscal year. The consolidated balance sheets for March 31, 2025 and March 31, 2024, and the consolidated statements of operations for the fiscal years ended March 31, 2025 and 2024 follow at the end of this release. Conference Call Management will host a conference call today, Thursday, June 26, 2025, at 4:30 p.m. ET to review the company's financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to Please note that registered participants will receive their dial-in number upon registration. Interested parties without internet access or unable to pre-register may dial in by calling: PARTICIPANT DIAL IN (TOLL-FREE): 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442 All callers should ask for the Aethlon Medical, Inc. conference call. A replay of the call will be available approximately one hour after the end of the call through July 26, 2025. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll-free at 1-855-669-9658. The replay conference ID number is 4903201. About Aethlon and the Hemopurifier®Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trials in Australia and India, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ AETHLON MEDICAL, INC. AND SUBSIDIARY Condensed Consolidated Balance Sheets Unaudited ASSETS March 31, 2025March 31, 2024CURRENT ASSETS Cash and cash equivalents$ 5,501,261$ 5,441,978 Deferred offering costs-277,827 Prepaid expenses and other current assets448,539505,983 TOTAL CURRENT ASSETS5,949,8006,225,788Property and equipment, net676,2201,015,229 Operating lease right-of-use asset601,846883,054 Patents, net5501,100 Restricted cash97,81387,506 Deposits33,30533,305 TOTAL ASSETS$ 7,359,534$ 8,245,982LIABILITIES AND STOCKHOLDERS' EQUITYCURRENT LIABILITIES Accounts payable$ 534,524$ 777,862 Due to related parties579,565546,434 Operating lease liability, current portion313,033290,565 Accrued professional fees472,164215,038 TOTAL CURRENT LIABILITIES1,899,2861,829,899Operating lease liability, less current portion336,718649,751 TOTAL LIABILITIES2,236,0042,479,650 STOCKHOLDERS' EQUITYCommon stock, $0.001 par value; 60,000,000 shares authorized as of March31, 2025 and 2024; 2,585,239 and 328,716 shares issued and 2,010,739 and328,716 outstanding as of March 31, 2025 and March 31, 2024, respectively2,586329 Additional paid-in capital173,092,894160,339,671 Accumulated other comprehensive loss(17,133)(6,940) Accumulated deficit(167,954,817)(154,566,728) TOTAL STOCKHOLDERS' EQUITY5,123,5305,766,332 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 7,359,534$ 8,245,982 AETHLON MEDICAL, INC. AND SUBSIDIARY Consolidated Statements of Operations and Comprehensive Loss For the fiscal years ended March 31, 2025 and 2024 Unaudited Fiscal YearFiscal Year Ended 3/31/25Ended 3/31/24OPERATING EXPENSES Professional fees$ 2,224,092$ 3,526,926 Payroll and related expenses3,874,0925,206,451 General and administrative3,243,1813,903,191 Total operating expenses9,341,36512,636,568OPERATING LOSS(9,341,365)(12,636,568)OTHER EXPENSE (INCOME), NET Interest income(298,122)(447,356) Other income(324,450)- Interest expense10,109- Other expense4,659,18818,962 Total other expense (income)4,046,725(428,394)NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS(13,388,090)(12,208,174)Basic and diluted net loss per share attributable to common stockholders$ (8.58)$ (38.87)Weighted average number of common shares outstanding - basic and diluted 1,560,839314,097NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS(13,388,090)(12,208,174)OTHER COMPREHENSIVE INCOME/(LOSS)(10,193)(799)COMPREHENSIVE LOSS$ (13,398,283)$ (12,208,973) View original content: SOURCE Aethlon Medical, Inc.

‘Nautilus' Review: On AMC, a Nemo Origin Story
‘Nautilus' Review: On AMC, a Nemo Origin Story

Wall Street Journal

time2 days ago

  • Wall Street Journal

‘Nautilus' Review: On AMC, a Nemo Origin Story

A steampunk 'Star Wars' with a dash of Jack Sparrow, the 10-part submarine saga 'Nautilus' is gaudy with pipes, valves, clocks, brass, pewter, swords, guns, anachronisms, a periscope that looks like it fell off a corner of Notre-Dame and a junkyard of sci-fi and action-movie quotations. 'Follow me if you want to live!' commands one very shortlived character, just before she's eaten by a Jurassic-inspired 'slug-lizard fish.' The title craft is piloted through treacherous oceans as if it were the Millennium Falcon. The story's Empire—or Skynet, or Mordor, or Death Eaters—is the British East India Company. This is all very self-aware stuff, and 'Nautilus' is what one might call a big old action-adventure series of Victorian vintage. And, in this case, a prequel: Drawing on the allusions contained in Jules Verne's classic 'Twenty Thousand Leagues Under the Sea,' the AMC series is essentially the origin story of Captain Nemo (Shazad Latif), aka Prince Dakkar, who has a justifiable grudge against the English: He has lost his family and lands to Company violence; he, the engineer Benoit (Thierry Frémont) and a crew of fellow Indian prisoners have developed the Nautilus, an underwater craft that resembles a crocodile on the surface and a shark when it dives, and carries more scrollwork than a Purdey rifle circa 1869 (the year 'Twenty Thousand Leagues Under The Sea' began serialization). Benoit thinks the ship has been created for exploration, but Company director Crawley (a name with period literary echoes, as well as that of the malignant character played by Damien Garvey) has other plans, mainly to use the cutting-edge craft to seal his company's control of waterways and trading routes. Crawley is surprised to learn that Nemo knows that his name means 'no one' in Latin. But it won't be the last thing that brings him up short. And short of one submarine.

Astronaut becomes first Indian to set foot on ISS
Astronaut becomes first Indian to set foot on ISS

Yahoo

time2 days ago

  • Yahoo

Astronaut becomes first Indian to set foot on ISS

Astronaut Shubhanshu Shukla has created history by becoming the first Indian ever to set foot on the International Space Station (ISS). A live broadcast showed the Axiom-4 (Ax-4) mission docking with the orbiting laboratory and its four-member crew crossing over to the ISS. Led by former Nasa veteran Peggy Whitson and piloted by Group Captain Shukla, Ax-4 lifted off on Wednesday. The crew, including Slawosz Uznanski-Wisniewski from Poland and Tibor Kapu from Hungary, will spend two weeks on the ISS. Group Captain Shukla is only the second Indian to travel to space. His trip comes 41 years after cosmonaut Rakesh Sharma became the first Indian to fly aboard a Russian Soyuz in 1984. Ax-4 - a commercial flight operated by Houston-based private firm Axiom Space - lifted off from Nasa's Kennedy Space Center in Florida at 02:31 EDT (06:31 GMT; 12:01 India time) on Wednesday. The docking on Thursday occurred at 06:31EDT (10:31 GMT; 16:01 India time). A pressurised vestibule was created between the spacecraft and the space station and then hatches were opened on both sides to allow the Ax-4 crew to make their way on board the ISS. With their arrival, the total crew strength of ISS is now 11. The Indian pilot set for a historic space journey on Axiom-4 Sweets to toy swan - what Indian astronaut will take on historic space voyage The mission is a collaboration between Nasa, India's space agency Isro, European Space Agency (Esa) and SpaceX. The two European astronauts will also be taking their countries back to space after more than four decades. During their two-week mission, the crew would spend most of their time conducting 60 scientific experiments, including seven designed by Indian Space Research Organisation (Isro). Isro, which has paid 5bn rupees ($59m; £43m) to secure a seat for Group Captain Shukla on Ax-4 and his training, says the hands-on experience he will gain during his trip to the ISS will help India in its human space flights. Isro has said it wants to launch the country's first-ever human space flight in 2027 and has announced ambitious plans to set up a space station by 2035 and send an astronaut to the Moon by 2040. Earlier on Thursday, Axiom Space had a live uplink with the astronauts on board where Group Captain Shukla spoke about his first 24 hours in space. "What a ride!," he said, adding that it has been "an amazing feeling to be just floating in space" and that "it's been fun time". "I was not feeling great when we got shot into vacuum, but I'm told I've been sleeping a lot, which is a great sign," he said laughing. "I'm enjoying the view, the experience and learning anew, like a baby, how to walk, to control yourself and to eat and read," he added. As Group Captain Shukla and other crew members spoke, Joy - a small, white toy swan described as Ax-4's "fifth crew member" - floated in and out of vision. Axiom has said Joy is "more than a cute companion for the Ax-4 crew" and is travelling to space as their "zero-G [zero-gravity] indicator". During Thursday's broadcast, Group Captain Shukla said the baby swan "symbolises wisdom and ability to discern what is important and what is not" which made it "so important in this age of distractions". Soon after Wednesday's launch, Commander Peggy Whitson revealed the name of their vehicle: Grace. "Grace is more than a name," she said. "It reflects the elegance with which we move through space against the backdrop of Earth. It speaks to the refinement of our mission, the harmony of science and spirit, and the unmerited favour we carry with humility." The name, she added, was a reminder "that spaceflight is not just a feat of engineering, but an act of goodwill - for the benefit of every human, everywhere".

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store